Apparent left ventricular cavity dilatation during PET/CT in hypertrophic cardiomyopathy: Clinical predictors and

Paco E Bravo1,2, Abdel Tahari3, Iraklis Pozios4

  • 1Department of Radiology, Johns Hopkins University, Baltimore, MD, USA. pbravo@uw.edu.

Insights

Apparent left ventricular cavity dilatation (LVCD) in hypertrophic cardiomyopathy (HCM) is linked to impaired blood flow and increased heart muscle thickness. These findings suggest both perfusion issues and potential true chamber enlargement contribute to LVCD in HCM patients.

Area of Science:

  • Cardiology
  • Nuclear Medicine
  • Medical Imaging

Background:

  • Apparent left ventricular cavity dilatation (LVCD) is observed in hypertrophic cardiomyopathy (HCM) but its underlying mechanisms are not fully understood.
  • Investigating the clinical predictors and potential causes of LVCD in HCM is crucial for patient management.

Purpose of the Study:

  • To explore the clinical predictors of apparent left ventricular cavity dilatation (LVCD) in patients with hypertrophic cardiomyopathy (HCM).
  • To investigate the potential mechanisms contributing to LVCD in HCM, focusing on myocardial perfusion and flow reserve.

Main Methods:

  • Sixty-one HCM patients underwent N-13-ammonia PET imaging.
  • Evaluated parameters included visual assessment of LVCD, transient ischemic dilatation (TID) index, myocardial blood flow (MBF), coronary flow reserve (CFR), and regional myocardial perfusion (rMP).
  • TID index was measured at different time points (2-4 min and 15-20 min).

Main Results:

  • Excellent agreement was found between visual LVCD and quantitative TID index.
  • LVCD-positive patients exhibited greater left ventricular (LV) thickness but lower stress MBF and CFR compared to LVCD-negative patients.
  • Abnormal regional myocardial perfusion (rMP) and a higher TID index at early time points were significantly associated with LVCD.

Conclusions:

  • Apparent LVCD in HCM is common and strongly associated with abnormal myocardial perfusion and impaired vasodilator flow reserve.
  • The degree of LV hypertrophy plays a role in the development of apparent LVCD.
  • Both regional/diffuse subendocardial ischemia and true LV chamber dilatation may contribute to apparent LVCD in HCM.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
754
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
966
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
485
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
681
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K